TABLE 1.
Material(s) injected | No. of embryos examineda | No. of embryos with normal or abnormal phenotypes (%)
|
|||
---|---|---|---|---|---|
Normal | Abnormalb
|
Lethal | |||
Tectum swelling | Blood circulation | ||||
Control MO (6 ng) | 173 | 170 (98%) | 0 (0%) | 0 (0%) | 3 (2%) |
Control MO (9 ng) | 53 | 52 (98%) | 0 (0%) | 0 (0%) | 1 (2%) |
zMelk-like gene RNA (300 pg) | 182 | 178 (98%) | 0 (0%) | 0 (0%) | 4 (2%) |
zMelk-like gene 5′mt RNA (300 pg) | 68 | 67 (99%) | 0 (0%) | 0 (0%) | 1 (1%) |
zMelk-like geneT169A RNA (300 pg) | 32 | 30 (94%) | 0 (0%) | 0 (0%) | 2 (6%) |
zMelk-like gene first MO (6 ng) | |||||
zMelk-like gene first MO (6 ng) | 192 | 14 (7%) | 171 (89%) | 174 (91%) | 4 (2%) |
zMelk-like gene first MO (6 ng) + EGFP RNA (300 pg) | 120 | 9 (8%) | 107 (89%) | 108 (90%) | 3 (2%) |
zMelk-like gene first MO (6 ng) + zMelk-like geneRNA (300 pg) | 75 | 53 (71%) | 21 (28%) | 21 (28%) | 1 (1%) |
zMelk-like gene first MO (6 ng) + zMelk-like gene 5′mtRNA (300 pg) | 88 | 62 (70%) | 24 (27%) | 25 (29%) | 1 (1%) |
zMelk-like gene first MO (6 ng) + zMelk-like geneT169A RNA (300 pg) | 58 | 4 (7%) | 48 (83%) | 51 (88%) | 3 (5%) |
zMelk-like gene second MO (6 ng) | |||||
zMelk-like gene second MO (6 ng) | 167 | 69 (41%) | 66 (40%) | 95 (57%) | 3 (2%) |
zMelk-like gene second MO (6 ng) + EGFP RNA (300 pg) | 111 | 43 (39%) | 44 (40%) | 66 (59%) | 2 (2%) |
zMelk-like gene second MO (6 ng) + zMelk-like geneRNA (300 pg) | 70 | 58 (83%) | 11 (16%) | 12 (17%) | 0 (0%) |
zMelk-like gene second MO (9 ng) | |||||
zMelk-like gene second MO (9 ng) | 154 | 14 (9%) | 66 (43%) | 137 (89%) | 3 (2%) |
zMelk-like gene second MO (9 ng) + EGFP RNA (300 pg) | 102 | 10 (10%) | 47 (46%) | 90 (88%) | 2 (2%) |
zMelk-like gene second MO (9 ng) + zMelk-like gene RNA (300 pg) | 70 | 52 (74%) | 11 (16%) | 18 (26%) | 0 (0%) |
One- or two-cell-stage embryos were injected with the materials indicated.
Number (%) of embryos with abnormal phenotypes, i.e., disintegration of the tectum region due to abnormal swelling or abnormal blood circulation.